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Validation of CLOZUK
Gene annotations Gene set enrichment test
Enrichment beyond CNS-related terms each of the three contributing studies. The total number/rate of these 11 loci in cases and controls is also given for each study. In this table only CNVs spanning an entire locus are counted; for analyses involving the removal of known loci, all CNVs overlapping these loci are removed (see Supplemental Experimental Procedures).
Table S3: Enriched CNS gene-sets, known loci removed, Related to Tables 2-4
Initial columns summarise the association data for CNS gene sets with Bonferroni corrected p-value < 0.05 in each of the three analyses: deletions and duplications being analysed together (Combined) or separately. The final two columns give the sign of the regression coefficient and uncorrected p-value for each gene set when CNVs overlapping wellsupported schizophrenia loci were removed. Gene sets with P uncorrected < 0.05 after removal of known loci are highlighted in bold.
Table S4: Enriched CNS gene sets, single-gene association (combined), Related to Results
For each CNS gene set with Bonferroni corrected p-value < 0.05 in the analysis of deletions and duplications combined, this table lists those genes with an uncorrected single-gene association p-value < 0.05 (again, in a combined analysis of deletions and duplications together). In addition to gene identifiers and chromosomal locations, the table lists the number of case and control CNVs that overlap the gene (N case and N ctrl respectively), raw and Bonferroni corrected p-values (P, P adjusted), and whether the gene is found in a well-supported schizophrenia CNV locus (known locus, locus type). Bonferroni correction is for the total number of single gene tests. Genes lying outside the boundaries of a known CNV locus, but whose association signal was clearly driven by that locus, were annotated as lying in 'xxx (extended)', where xxx is the corresponding locus. Table S4 .
Table S7: MGI gene set association, conditional analysis, Related to Results
Association results for all MGI gene sets tested in the combined analysis of deletions and duplications together and the analysis of deletions or duplications separately. Uncorrected (P) and Bonferroni corrected (P adjusted) one-sided conditional p-values for enrichment in case CNVs are given, together with the gene set name, id and number of autosomal genes (N gene).
Table S8: GO gene set association, conditional analysis, Related to Results
Association results for all GO gene sets tested in the combined analysis of deletions and duplications together and the analysis of deletions or duplications separately. Uncorrected (P) and Bonferroni corrected (P adjusted) one-sided conditional p-values for enrichment in case CNVs are given, together with the gene set name, id and number of autosomal genes in each set (N gene). Table 5 For each gene set with a Bonferroni corrected P < 0.05 identified by our analyses (Tables 2-4) , we investigated enrichment for non-synonymous (NS) de novo rare variants from individuals with schizophrenia. Here we list the number of genes in each gene set (N gene); the number of de novo rare variants found within these genes (N observed); the number of variants expected (N expected); plus uncorrected (P) and Bonferroni corrected (P adjusted) p-values. For comparison, this analysis was then repeated using NS de novo rare variants identified in controls, with exactly the same correction procedure. See Experimental
Procedures for the source of variants used. 
Discussion
Single-gene CNV counts and enrichment p-values for all genes in the GABA receptor complex gene set. Genes found on the X chromosome, which was not analysed here, are listed for completeness. Columns are as given in Tables S4-S6 . 
Supplemental Tables
CLOZUK
A full description and ascertainment of the CLOZUK cases is given in (Rees, Walters et al. 2014, PMID: 24163246) . Briefly, the case sample utilised here consists of patients taking clozapine. Blood was obtained from these patients through collaboration with Novartis, the manufacturer of a proprietary form of clozapine (Clozaril). These patients were aged 18-90 and had received a recorded diagnosis of treatment resistant schizophrenia. In the UK, treatment resistant schizophrenia implies a lack of satisfactory clinical improvement to adequate trials of at least two other antipsychotics. We excluded those with diagnoses other than treatment resistant schizophrenia and those prescribed clozapine for off-license indications. All cases were genotyped on either Illumina HumanOmniExpress-12v1 or Illumina HumanOmniExpressExome-8v.1 arrays.
The CLOZUK control sample has been described previously (Rees et al., 2014) . This sample consisted of four non-psychiatric control datasets obtained from either the Database of Genotypes and Phenotypes (dbGaP) or the European Genome-Phenome Archive (EGA).
These four datasets were derived from a study on smoking and smoking cessation (dbGaP phs000404.v1.p1), melanoma (dbGaP phs000187.v1.p1), refractive error (dbGaP phs000303.v1.p1) and WTCCC2 (EGA EGAD00000000024 and EGAD00000000022), which combined amount to 12,080 samples before QC. These were genotyped on Illumina HumanOmni2.5, Illumina HumanOmni1_Quad_v1-0-B, Illumina HumanOmni2.5 and Illumina
1.2M arrays respectively (see table above).
Principal component analysis (PCA) was performed to derive the ancestries of the CLOZUK cases and controls by combining the data with Hapmap genotypes. Samples were stratified probes common to all Illumina arrays used to genotype the CLOZUK sample. Samples were subjected to rigorous QC and excluded if for any one of the following metrics they
represented an outlier in their source dataset: Log R ratio standard deviation, B-allele frequency drift, wave factor and total number of CNVs called per person.
Molecular Genetics of Schizophrenia (MGS)
Details of the MGS cohort have been described elsewhere (Levinson et al., 2011) . Our CNV analysis and QC of this sample has also been described previously (Rees et al., 2014a) .
Briefly, the samples were genotyped at the Broad Institute, Cambridge, Massachusetts, using Affymetrix 6.0 genotyping arrays. All schizophrenic patients met DSM-IV criteria for schizophrenia or schizoaffective disorder. CNVs were called using the Birdsuite algorithm (Korn et al., 2008 
Additional CNV QC for CLOZUK, ISC and MGS
For individuals/CNVs passing QC procedures performed by the original studies, CNV calls were joined if the distance separating them was less than 50% of their combined length.
CNV calls were excluded if they overlapped with low copy repeats by more than 50% of their length, or had a probe density (calculated by dividing the size of the CNV by the number of probes covering it) less than 1 probe/20kb. We used PLINK (Purcell et al., 2007) to remove
CNVs with a frequency > 1% in their respective sample (CLOZUK, ISC or MGS). We then applied an in silico median Z-score outlier method of CNV validation, described in detail elsewhere (Kirov et al., 2012; Rees et al., 2014) , to all remaining CNVs. This method has been shown to be effective for the removal of false positive CNV calls and detecting CNVs missed by calling (Kirov et al., 2012) . We did not perform Z-score validation for the ISC study as we did not have access to the raw intensity data.
Following QC (performed separately for each study), protein-coding genes overlapping CNVs were identified using genomic locations for the appropriate build of the human In performing gene set enrichment analyses we specifically included covariates for genotyping chip and study to remove any biases due to differences between Affymetrix 5.0, Affymetrix 6.0 and Illumina arrays and between the cohorts used in each individual study.
We would add that since matched sets of cases and controls were genotyped on each Affymetrix array, the use of multiple chips in ISC and MGS does not cause an increase in false positives. To investigate whether batch effects in CLOZUK (due to the multiple sources of controls) were driving our results, we took all CNS-related gene sets with a Bonferroni corrected p-value < 0.05 and tested for significant differences in CNV overlap between controls genotyped in different studies or on different chips. This was performed using the same logistic regression model as the case-control CNV enrichment test from our primary analysis, but with 'cases' now being control CNVs from one study/chip and 'controls' being control CNVs from a different chip/study (and obviously using no covariates for chip or study). Calculating two-sided p-values for all potential chip-chip and control study-control study pairings, there were no significant differences after correcting for the number of comparisons made (data not shown).
Validation of CLOZUK: Validation of Clinical Diagnosis
We used the Cardiff Cognition in Schizophrenia (Cardiff COGS) sample to assess the validity of a psychiatrist-assigned diagnosis of treatment resistant schizophrenia as applied in CLOZUK. The Cardiff COGS sample is a conventional sample of those with schizophrenia recruited via secondary care, mainly outpatient, mental health services in Wales and
England. The recruitment procedures included inviting patients from clozapine clinics, irrespective of diagnosis. Consenting participants were interviewed with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) (Wing et al., 1990 ) and consensus research diagnoses were agreed with reference to the interview and clinical notes according to DSM-IV criteria.
Validation Procedure
Prior to the research interview we obtained clinicians' diagnoses for all participants in Cardiff COGS. From participants on clozapine we selected those with a clinical diagnosis of schizophrenia and confirmed that this matched the diagnosis provided when the participant was started on clozapine (i.e. treatment resistant schizophrenia) so as to be equivalent to the samples identified as having schizophrenia in CLOZUK. We then compared this diagnosis with the consensus research DSM-IV diagnosis.
Results
We identified 214 participants within CardiffCOGS (n=905) who were taking clozapine and had a clinician-assigned diagnosis of treatment resistant schizophrenia. Following consensus research diagnosis, 194 of these participants were identified as having DSMIV schizophrenia or schizoaffective disorder depressed sub-type, giving a positive predictive value (PPV) of 90.7%.
Many international groups and consortia also consider other diagnoses as 'schizophrenia' samples, namely schizoaffective disorder bipolar type, delusional disorder and schizophreniform disorders (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). If we expand our analysis to include these categories then 210 of 214 (PPV=98.1%) of those on clozapine with a clinical diagnosis of schizophrenia would receive a DSMIV research diagnosis of one of these schizophrenia spectrum disorders.
These results are entirely consistent with equivalent reports of the validity of clinician diagnoses in two Scandanavian studies (Ekholm et al., 2005; Jakobsen et al., 2005) .
Molecular/Genetic Validation
In the largest GWAS meta-analysis to date, the schizophrenia working group of the Psychiatric Genomics Consortium identified 40 target subgroups within their primary GWAS analysis and performed a leave-one-out analysis (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). Using risk alleles identified in the remainder of the primary sample, polygenic risk profile scores were calculated for all individuals in the target subgroup; the ability of these scores to distinguish between cases and controls was then (Table S2 of this paper).
Taken together, the clinical and molecular evidence strongly validate CLOZUK as a schizophrenia sample.
Gene annotations
The ARC and NMDAR network gene sets used here were taken from (Kirov et al., 2012) ; the GABA A receptor complex gene set is listed in Table S10 . All other gene sets are available from the authors upon request.
GO
Gene Ontology (GO) annotations were taken from NCBI gene2go
(ftp://ftp.ncbi.nih.gov/DATA), using Homo Sapiens annotations only. Parent terms were identified for each GO term through the AmiGO ontology (http://www.geneontology.org/GO.downloads.ontology.shtml). We used "is_a" and "part_of" (but not "regulates") to define child-parent relationships between terms. The parent terms of each GO term assigned to a gene in gene2go were also assigned to that gene. When performing enrichment analyses we restricted to GO terms containing between 20 and 2000 autosomal genes, a total of 4026 terms.
MGI
The Mammalian Phenotype (MP) ontology and gene annotations were downloaded from the Mouse Genome Database (Blake et al., 2011) within the Mouse Genome Informatics (MGI) online resource (http://www.informatics.jax.org). Gene annotations arising from transgene and multi-gene manipulations were removed. Parent terms were identified for each MP term and assigned to all genes annotated with that child term. Genes were mapped to human using file HOM_MouseHumanSequence.rpt, also downloaded from MGI. Within this file human and mouse genes are organised into orthologous groups identified by HomoloGene id. To ensure the unambiguous annotation of human genes, we discarded all phenotypic information from mouse genes with non-unique (1-many, many-1, many-many) orthology relationships (i.e. HomoloGene groups containing multiple mouse and/or human gene ids).
When performing enrichment analyses we restricted to MGI terms with more than 20 autosomal genes, a total of 2616 terms (of which 118 were extracted for use as CNS-related gene sets). As MGI terms relate to specific biological processes we felt there was no need to place an upper bound on gene set size, used above to remove extremely large, generic GO annotations.
Gene set enrichment test
For each gene set, the number of genes 'hit' by case and control CNVs were compared; a gene was counted as being hit by a CNV if the CNV overlapped any part of its length. To overcome biases related to gene and CNV size, and to control for differences between studies and genotyping chips, the following logistic regression models were fitted to the combined set of CNVs:
(a) logit (pr(case)) = study + chip + CNV size + total number of genes hit (b) logit (pr(case)) = study + chip + CNV size + total number of genes hit + number of genes hit in gene set
Comparing the change in deviance between models (a) and (b), a one-sided test for an excess of genes in the gene set being hit by case CNVs was performed.
By comparing case to control CNVs, this analysis allows for the possibility of non-random CNV location unrelated to disease (i.e. CNVs tend to occur in specific locations of the genome and this is unrelated to case status, both in cases and controls). The inclusion of CNV size in the regression allows for the fact that case CNVs are larger than control CNVs (and thus likely to hit more genes, regardless of function), even when restricting to those >100kb in length (see Results). Inclusion of the total number of genes hit in the regression corrects for case CNVs hitting more genes overall (regardless of function) than control
CNVs. It should also be noted that since we compare between cases and controls, gene size (which is the same in cases and controls) is not a source of potential bias: CNVs of given size have exactly the same chance of overlapping a particular gene in both cases and controls.
Since case and control samples from the CLOZUK study were genotyped on different chips, we were unable to completely control for possible inter-chip differences. This is unlikely to influence our analyses: calling is most robust for large CNVs; calling was restricted to probes present on all arrays; and the arrays used were in any case comparable in coverage ( Additional QC' above); no significant differences were found.
Enrichment beyond CNS-related terms
To determine whether any GO or MGI annotation showed evidence for enrichment in case
CNVs that was independent of the association signal captured by CNS-related gene sets, the following regression models were fitted.
(a) logit (pr(case)) = study + chip + CNV size + total number of genes hit + CNS terms (b) logit (pr(case)) = study + chip + CNV size + total number of genes hit + CNS terms + number of genes hit in gene set (from GO or MGI)
where CNS terms = number of genes hit in CNS gene set X + number of genes hit in CNS gene set Y + … These were constructed by adding a subset of CNS terms, capturing the enrichment signal arising from all CNS gene sets with P corrected < 0.05, to the regression models described earlier (see 'Enrichment test' above). The identification of this CNS subset is described in the main text and in greater detail below, its sole purpose being to minimise the number of additional model parameters to be fitted (i.e. compared to adding all CNS terms with P corrected < 0.05). Comparing the change in deviance between models (a) and (b), a one-sided test for an excess of genes in the GO or MGI gene set being hit by case CNVs was performed.
Identification of 'minimal set' capturing association signal in enriched CNS terms
To capture the enrichment signal arising from CNS gene sets with P corrected < 0.05, we added the most significant such term as a covariate to the regression model and recalculated gene set enrichment for each of the remaining terms. The term with the most significant residual enrichment was then added to the model and the process repeated until there was no residual association (P uncorrected < 0.05) in the remaining terms. This iterative procedure is captured in the tables below. Initial columns (up to P) summarise the association data for The GABA A gene set, which has the most significant residual association, is then added to (a) and the process repeated until no term has a residual P uncorrected < 0.05 (see final column in 'Combined' 
Removing signal from known loci
To investigate whether gene set enrichment was solely driven by CNVs at loci well supported by current data, we removed all CNVs overlapping these loci and re-ran the enrichment analysis. To identify CNVs for removal, we collated a list of all genes lying in known CNV loci, plus any neighbouring genes whose association signal was also clearly driven by these loci. CNVs hitting one or more of these genes were then removed prior to reanalysis. When analysing deletions all known deletion loci were removed; when analysing duplications all known duplication loci were removed; and when analysing deletions and duplications combined, all CNVs overlapping a known locus were removed irrespective of their class (deletion/duplication).
In order to calculate odds ratios for enriched gene sets, the following logistic regression model was fitted to the full set of individuals from each study (i.e. including those in which no large CNVs were identified):
logit (pr(case)) = study + average CNV size + number of CNVs + total number of genes hit + number of genes hit in gene set where 'average CNV size' is the mean length of all CNVs >100kb for that individual; 'number of CNVs' is the total number of CNVs > 100kb for that individual; 'total number of genes hit'
and 'number of genes hit in gene set' count the corresponding number of unique genes hit by these CNVs (any gene hit by two CNVs would only count once). The odds ratio was derived from the coefficient of the 'number of genes hit in gene set' term. Since the unit of analysis is now the individual rather than the CNV, we control for average CNV length and CNV number in line with the recommendations of (Raychaudhuri et al., 2010) .
CNV size and number of genes hit as predictors of case-control status
When investigating the relationship between CNV size, number of genes hit and casecontrol status, the following four models were fitted:
(a) logit (pr(case)) = study + chip To test for enrichment with rare, non-synonymous de novo mutations from individuals with schizophrenia, the 'minimal set' of terms that capture most of the CNS enrichment signal were collapsed into a single gene set for each of our analyses (combined, deletion and duplication). Results were Bonferroni corrected for these 3 tests. An ancillary analysis was then performed to investigate whether the association signals identified were solely due to ARC and NMDAR genes. As we only explore the source of enrichment signals and do not claim to find novel associations, p-values for these tests are uncorrected. To check that enrichment was not due to some property of NS variants unrelated to disease, the analysis was then repeated using NS de novo rare variants identified in unaffected individuals.
Results were again corrected for 3 tests. Analyses of the 21 individual gene sets listed in Table S9 were Bonferroni corrected for 3 + 21 = 24 tests.
2) Since ISC and MGS data had previously been used to investigate CNV enrichment for ARC and NMDAR (Kirov et al., 2012) , we were interested in investigating whether the enrichment seen in the present combined ISC-MGS-CLOZUK sample was solely due to ISC and MGS. As we are simply investigating the partitioning of the association signal between datasets, it does not make sense to correct for tests performed in the full sample. CLOZUKonly results for the combined CNV analysis and for the analysis of deletions and duplications separately were corrected for 9 tests.
Prior to discussing CNV enrichment for individual CNS gene sets, we investigate whether the 134 sets as a whole display more evidence of nominal association than would be expected by chance, performing permutation tests at two p-value thresholds separated by an order of magnitude (0.01 and 0.001) (see Table 1 ). Results are corrected for 6 tests, corresponding to the 2 thresholds x 3 analyses (combined, deletion only and duplication only).
To quantify the effect of removing known loci we employed a permutation test in exactly the same manner, results being given in the lower half of ( Table 1 ). The correction procedure here is identical.
To identify genes contributing most to gene set enrichment we calculated single gene association p-values, listing genes with uncorrected P < 0.05 in Tables S4-S6 . The number of genes tested in each analysis were: 10200 for the combined analysis, 3918 for deletions and 8759 for duplications, these being the number of genes overlapping at least one contributing CNV. In these tables, single gene enrichment p-values are corrected for the full 10200 + 3918 + 8759 = 22877 single gene tests.
The section investigating correlation between case-control status and CNV size and number of genes disrupted falls outside the two main classes of analysis discussed above. The initial analysis of size and number of genes is corrected for 4 tests (size and number in deletions and duplications), the subsequent 2 tests for CNS SZ are corrected for the full set of 6 tests.
Conditional analyses, in which we only explore the source of enrichment signals and do not claim to find novel associations, remain uncorrected.
